polycystic ovarian syndrome: PCOS. Sclerocystic ovary syndrome-Stein-Leventhal syndrome
Conditions
Interventions
Tablets NAC (Alborz ?Darou Pharmaceutical company) - per tablet dose of 600 mg - by three per day - 6 weeks
Placebo (Alborz Darou Pharmaceutical company)- three per day to 6 weeks
Intervention 1: Tablets NAC (Alborz ?Darou Pharmaceutical company) - per tablet dose of 600 mg - by three per day - 6 weeks. Intervention 2: Placebo (Alborz Darou Pharmaceutical company)- three per da
Treatment - Drugs
Sponsors
Vice chancellor for research, Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
25 Years to 35 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for patients: Diagnosis of PCOS according to the Rotterdam criteria, aged between 25 and 35 years, the lack of Oral contraceptive pill (OCP) and hormone analogues Apart from progesterone , The use of assisted reproductive medicine at the same dose in all cases, the absence of other systemic diseases known, the first IVF cycle in patients. exclusion criteria for patients : Hyperprolactinemia, thyroid disease, congenital adrenal hyperplasia, testosterone-secreting tumors, Cushing, endometriosis, FSH above 10 IU / L on the third day after menstrual bleeding, Use of drugs that affect the metabolism of carbohydrates, using an analog of the hormone progesterone than three months before entering the study and severe kidney and liver diseases.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Apoptosis. Timepoint: 6 weeks after intervention. Method of measurement: Real Time PCR. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Azvan
Iran University of Medical Sciences
Outcome results
None listed